文献速递脊柱关节炎

ASAS项目:中轴与外周脊柱关节炎外周关节炎评估工具选择

Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project.
PubMed 文献 · Ann Rheum Dis · 2026-07-07

该ASAS项目遵循OMERACT框架,通过系统文献综述、工作组评估、13项RCT个体患者数据分析及ASAS共识投票,筛选评估axSpA和pSpA外周关节炎疾病活动度的最佳工具。复合工具优于单一关节计数,DAPSA44在全部测量属性中表现最佳,获ASAS推荐用于pSpA临床研究。

要点

  • 复合疾病活动度工具在外周关节炎评估中一致优于单一项目测量。
  • DAPSA44在axSpA和pSpA中测量性能最佳,ASAS投票支持率分别为92%和97%。
  • 未来SpA外周关节炎临床研究应报告DAPSA44。

核心结论

  • DAPSA44在axSpA和pSpA中展现出最充分的测量性能,被ASAS推荐为pSpA临床研究中评估外周关节炎相关疾病活动度的工具。

研究设计与样本

  • 本ASAS项目遵循OMERACT框架,通过系统文献综述识别候选工具,工作组评估领域匹配与可行性,第二项系统文献综述评估测量属性,并利用13项随机对照试验的个体患者数据补充分析,最终经工作组讨论和ASAS共识投票形成推荐。

主要发现

  • 复合疾病活动度工具一致优于单一项目测量。
  • 第二项系统文献综述证据有限,尤其对于伴外周关节炎的axSpA,但13项RCT分析增强了证据。
  • 在axSpA和pSpA中,BASDAI、ASDAS和DAPSA44等复合工具在结构效度、反应度和临床试验区分度方面优于单纯关节计数。
  • DAPSA44的临床试验区分度尤其更优,使其在全部测量属性中表现最佳。
  • ASAS投票后,DAPSA44成为首选工具,在axSpA中获得92%支持率,在pSpA中获得97%支持率。

关键数值与推荐

  • ASAS投票中DAPSA44在axSpA的同意率为92%,在pSpA的同意率为97%。

临床怎么用

  • 未来临床试验和研究在分析SpA外周关节炎相关疾病活动度时应报告DAPSA44。
  • DAPSA44被ASAS推荐用于pSpA临床研究中外周关节炎相关疾病活动度的评估。

局限性

  • 第二项系统文献综述证据有限,尤其对于伴外周关节炎的axSpA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify the most appropriate instrument to assess disease activity related to peripheral arthritis in axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) in clinical research. METHODS: This Assessment of Spondyloarthritis International Society (ASAS) project followed the Outcome Measures in Rheumatology (OMERACT) framework. Candidate instruments were identified through a systematic literature review (SLR). Domain match and feasibility were assessed by a working group (WG). A second SLR evaluated measurement properties (construct validity, test-retest reliability, responsiveness, clinical trial discrimination, and thresholds of meaning). Additional analyses were performed using individual patient data from randomised controlled trials (RCTs). Evidence was synthesised in summary of measurement properties tables, followed by a WG discussion and ASAS consensus voting. RESULTS: Composite disease activity instruments consistently outperformed single-item measures. Evidence from the second SLR was limited, particularly for axSpA with peripheral arthritis, but analyses of 13 RCTs strengthened the evidence. In both axSpA and pSpA, composite instruments, particularly the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Axial Spondyloarthritis Disease Activity Score (ASDAS), and Disease Activity index for Psoriatic Arthritis based on 44 joints (DAPSA44), showed better construct validity, responsiveness, and clinical trial discrimination than joint counts alone. Clinical trial discrimination was particularly better for DAPSA44, making it the best-performing instrument across all measurement properties. Following ASAS voting, DAPSA44 was the preferred instrument, receiving 92% agreement for axSpA and 97% for pSpA. CONCLUSIONS: DAPSA44 demonstrated the most adequate measurement performance across axSpA and pSpA and was endorsed by ASAS as the recommended instrument for assessing disease activity related to peripheral arthritis in pSpA clinical research. Future clinical trials and research studies should report DAPSA44 when analysing disease activity related to peripheral arthritis in SpA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ramiro S, Capelusnik D, López-Medina C, et al. Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project. Ann Rheum Dis. 2026. PMID: 42409723. doi:10.1016/j.ard.2026.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。